Uruguayan biotech Xeptiva raised a $2.5M seed round led by Zentynel, a Chilean fund specialized in biotechnology. iThink VC, FEN Ventures, ND Latam, Uruguay Biotech Ventures, and Co-founder of DLocal, Sergio Fogel, also participated in the round.
Xeptiva will use the funds to continue to develop vaccines for osteoarthritis pain and atopic dermatitis in pets.
“Our goal is to increase access to effective treatments for a greater number of patients,” said Josefina Correa, Xeptiva’s CEO.
Xeptiva Therapeutics develops and produces vaccines to treat chronic inflammatory conditions in pets. The vaccines are currently in clinical trials..
Founded in 2021 at the Neurodegeneration Laboratory of the Institut Pasteur in Montevideo, Xeptiva produced its first batch of osteoarthritis vaccines in 2024.
Read more on Tekios.
